Results 191 to 200 of about 22,035 (254)

Darunavir

Drugs of Today, 2007
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire   +4 more sources

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

Current Medicinal Chemistry, 2020
Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19).
M. Costanzo, Maria Anna Rachele De Giglio, G. Roviello   +2 more
semanticscholar   +1 more source

Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance.

Chemical Communications, 2022
We report our recent development of a conceptually new generation of exceptionally potent non-peptidic HIV-1 protease inhibitors that displayed excellent pharmacological and drug-resistance profiles.
Arun K. Ghosh, I. Weber, H. Mitsuya
semanticscholar   +1 more source

Pharmacoeconomics of darunavir

Expert Review of Pharmacoeconomics & Outcomes Research, 2011
Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton, Erik, Smets, Guy, De La Rosa, Joseph M, Mrus   +3 more
openaire   +2 more sources

Development of novel darunavir amorphous solid dispersions with mesoporous carriers.

European Journal of Pharmaceutical Sciences, 2021
The aim of this work was to compare mesoporous carriers based on silica and magnesium aluminosilicate in the amorphous solid dispersion production. Darunavir has been selected as an active pharmaceutical ingredient that is classified as a Class 2 BCS ...
S. Zolotov, N. Demina, A. Zolotova, N. Shevlyagina, G. A. Buzanov, V. M. Retivov, E. Kozhukhova, Oleg Y Zakhoda, I. A. Dain, A. R. Filatov, Alexander Cheremisin   +10 more
semanticscholar   +1 more source

Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation

Colloids and Surfaces B: Biointerfaces, 2019
The present work aimed to formulate Darunavir loaded lipid nanoemulsion to increase its oral bioavailability and enhance brain uptake. Various batches of lipid nanoemulsion of Darunavir were prepared by high pressure homogenization using soya bean oil ...
Jagruti L Desai, Hetal Thakkar
exaly   +2 more sources

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial.

The Lancet HIV
BACKGROUND Randomised comparative data on efficacy and safety of second-line antiretroviral therapy (ART) after failure of non-nucleoside reverse transcriptase inhibitors (NNRTIs) across diverse geographical settings are scarce. The aim of this study was
Gail V Matthews, S. Jacoby, Margaret Borok, N. Eriobu, Richard Kaplan, N. Kumarasamy, J. Bennet, A. Avihingsanon, P. Chetchotisakd, Sandra Wagner Cardoso, Iskander Azwa, M. Losso, Dannae Brown, D. Arlinda, J. Hutchinson, A. Kelleher, Mohamed Cissé, Sounkalo Dao, M. Polizzotto, Sean Emery, Matthew Law, Emmanuelle Papot, M. Karyana, S. Lupo, Ana Melisa Solari, B. Grinsztejn, M. Wolff, J. Andrade-Villanueva, J. L. Mosqueda Gómez, T. S. Chow, L. Mohapi, E. Yunihastuti, Usman Hadi, S. Katu, Y. Subronto, H. Lane, Leonardo Perelis   +36 more
semanticscholar   +1 more source

In Silico Investigation of Molecular Properties and Molecular Docking of Darunavir: An Anti‐HIV Drug

Macromolecular Symposia
A second‐generation HIV protease enzyme inhibitor, darunavir is used in combination therapy for patients with history of prior antiretroviral treatments.
Shiv Kumar, G.N. Tiwari, Dipendra Sharma
semanticscholar   +1 more source

UV Spectrophotometric Method Development and Validation of Darunavir in bulk and Solid Dosage Form

Research Journal of Pharmacy and Technology, 2021
Objective: A new, simple, sensitive, precise, reproducible UV visible spectrophotometric method was developed for the determination of Darunavir in Tablet dosage form with¬¬¬ 0.1N HCl.
V. Tegeli
semanticscholar   +1 more source

Darunavir: A comprehensive profile

2021
Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV).
Ibrahim A, Darwish, Abdulrahman A, Al-Majed, Nawaf A, Alsaif, Ahmed H, Bakheit, Rashed N, Herqash, Abdullah, Alzaid   +5 more
openaire   +2 more sources